Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC – an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie). Posted byadmin 28. July 2020 Huemer, F, Thaler, J, Piringer, G, Hackl, H, Pleyer, L, Hufnagl, C, Weiss, L, Greil, R. http://www.ncbi.nlm.nih.gov/pubmed/29298682